Alnylam Pharmaceuticals Announces Progress In Pre-clinical Programs At The 36th Annual Alnylam Pharmaceuticals Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it presented pre-clinical data at the 36th Annual Society for Neuroscience Meeting being held in Atlanta, Georgia from October 14-18, 2006. Alnylam, in an alliance with Medtronic, Inc., and with its academic collaborators, presented pre-clinical data from four ongoing neurology programs including Huntington’s disease, neuropathic pain, Parkinson’s disease, and dystonia. Accumulating data show that small interfering RNAs (siRNAs), the molecules that mediate RNAi, can be administered in vitro and in vivo in animal models of neurological diseases to achieve therapeutic silencing of disease-causing genes.